AstraZeneca PLC said Monday that the Calquence drug-inhibitor showed improvements in atrial fibrillation when compared with ibrutinib in previously treated adult patients with chronic lymphocytic leukemia.
The pharmaceutical giant said Calquence also proved to give favorable tolerability at four years.
The company said these final results of Calquence come from the head-to-head elevate-rr phase 3 trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.